I-Mab Biopharma
高管
查看带有其 13 名主要高管的组织结构图
I-Mab Biopharma 搜索最多的简介
高管在I-Mab Biopharma变化
- Xi-Yong Fu 曾任 Interim Chief Executive Officer, 现升职为 Chief Executive Officer (新闻发布的2024十一月8号).
- Wei Fu 曾任 Director, 现升职为 Chairman of the Board (新闻发布的2024七月16号).
- Phillip Dennis已作为Chief Medical Officer加入公司 (新闻发布的2024六月7号).
创建提醒
跟踪 I-Mab Biopharma 的高管变动
药店
I-Mab Biopharma 拥有 1,835 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
I-Mab Biopharma 的最新新闻稿
- I-Mab | I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
- I-Mab | I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
- I-Mab | News Releases
- I-Mab | I-Mab to Host 2022 R&D Day
- I-Mab | I-Mab Receives Top Rankings in Five Categories by Institutional Investor
- I-Mab | I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
- I-Mab | I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
- I-Mab | I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
- I-Mab | News Releases
- I-Mab | I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
- View more press releases Close
通过电子邮件
